Due to its evident role in proliferation and cancer, several CDK4/6 inhibitors have been generated, including palbociclib and ribociclib, which specifically target CDK4/6, and abemaciclib which targets CDK4/6 and other similar kinases (127). Here, CDK4 is linked to cancer.